July 3, 2025
Source: drugdu
49
On the evening of July 1, the company and its wholly-owned subsidiaries, Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., recently obtained the National Intellectual Property Rights of the People's Republic of China.An invention patent certificate issued by the Bureau, the patent name is "A primer pair and its application in BCG-CpG-DNA adjuvant quality control method", patent number ZL202211426011.7, patent certificate number 8029182, and the application date is November 14, 2022.
The company stated that the above invention patent was applied for and obtained during the research and development of the freeze-dried recombinant tuberculosis vaccine (AEC/BC02) independently developed by the company and still in the research stage, and will be used in the company's related products under research. The acquisition of this patent certificate will not have a significant impact on the company's recent production and operation, but it will help to further improve the company's intellectual property protection system, give full play to the advantages of independent intellectual property rights, promote technological innovation, and enhance the company's core competitiveness.
https://finance.eastmoney.com/a/202507013445366098.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.